NCAM1 and prostate carcinoma: Therefore, we examined the impact of ELAVL3 overexpression in prostate cancer cell lines and discovered that it effectively stimulated the expression of neuroendocrine markers, alongside MYCN, NCAM1, and SYP when compared with vector control (Fig. 2c and Supplementary Fig. S2b).